EP4058463A1 - Sel organometallique de nitroprusside en tant qu'agent liberant du no - Google Patents
Sel organometallique de nitroprusside en tant qu'agent liberant du noInfo
- Publication number
- EP4058463A1 EP4058463A1 EP20803605.3A EP20803605A EP4058463A1 EP 4058463 A1 EP4058463 A1 EP 4058463A1 EP 20803605 A EP20803605 A EP 20803605A EP 4058463 A1 EP4058463 A1 EP 4058463A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- nitroprusside
- formula
- chitosan
- salt
- organometallic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/02—Iron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/80—Preparations for artificial teeth, for filling teeth or for capping teeth
- A61K6/84—Preparations for artificial teeth, for filling teeth or for capping teeth comprising metals or alloys
- A61K6/842—Rare earth metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/114—Nitric oxide, i.e. NO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
Definitions
- the invention relates to the use of an organometallic salt of nitroprusside as an agent releasing NO, to a composite material comprising such an organometallic salt of nitroprusside, to an implant comprising such an organometallic salt of nitroprusside and to a process for the manufacture of this organometallic salt of nitroprusside.
- It also relates to a method for releasing NO and a method for decontaminating a substrate suspected of being contaminated with bacteria.
- Nitric oxide gas has many properties, including antibacterial and healing properties.
- NO gas has been used successfully for the treatment of pulmonary hypertension, where it is delivered directly to the lungs.
- Nitroprusside is generally used in the form of its sodium salt dihydrate of nitroprusside of the formula Na 2 [Fe (CN) 5 NO] .2H 2 O.
- ferrous nitroprusside of the formula [Fe (CN) 5 NO] .2H 2 O is known.
- This compound has a stable orthorhombic crystal structure.
- the electrochemical properties of this ferrous nitroprusside salt have been studied by doCarmo et al. in the article entitled "Electrochemical study of Fe [Fe (CN) 5 NO] in graphite paste electrode, ECLETICA QUIMICA, vol 27, pages 197-210, special issue: SI, 2002".
- the invention aims to overcome the problem of the release of five cyanide molecules when the sodium salt of nitroprusside releases NO.
- the invention proposes the use of an organometallic salt of nitroprusside of the following formula I:
- M II represents Zn II or Fe II
- 2 ⁇ x ⁇ 18 as agent releasing nitrogen monoxide NO.
- the nitroprusside salt is in the form of particles, the size of which (largest dimension of the particle) is between 50 nm and 6 mih.
- This size is measured by SEM scanning electron microscopy, up to a dimension of 200 nm and by transmission electron microscopy below 200 nm.
- the organometallic salt of nitroprusside of formula I is coated in a biopolymer such as chitosan, an alginate of the metal M (Zn or Fe), pectin, agar-agar, carrageenan, a copolymer lactic acid and gly colic acid (PLGA), a poly (L-lactide) polymer (PLLA), most preferably chitosan.
- a biopolymer such as chitosan, an alginate of the metal M (Zn or Fe), pectin, agar-agar, carrageenan, a copolymer lactic acid and gly colic acid (PLGA), a poly (L-lactide) polymer (PLLA), most preferably chitosan.
- the organometallic salt of nitroprusside of formula I is coated in the biopolymer to form a film or to form spheres.
- organometallic salt of nitroprusside of formula I When the organometallic salt of nitroprusside of formula I is coated in the biopolymer to form spheres, these spheres preferably have a diameter of between 1.5 mm and 4.5 mm. This diameter is measured using a graduated ruler and by SEM scanning electron microscopy). Still when the organometallic salt of nitroprusside of formula I is coated in the biopolymer to form spheres, the organometallic salt of formula I / biopolymer mass ratio is preferably between 2 and 60%.
- this film preferably has a thickness of between 30 mih and 1 mm.
- the organometallic salt of formula I / biopolymer mass ratio is preferably between 2 and 60%.
- organometallic nitroprusside salt of formula I When this ratio is greater than 10%, all the particles of organometallic nitroprusside salt of formula I are not completely coated in the biopolymer: some have a part on the surface, on the outside, of the film.
- the invention also provides an organometallic salt of nitroprusside of the following formula I: [Chem.2]
- the organometallic salt of nitroprusside of formula I is in the form of particles having a size between 50 nm to 6 ⁇ m.
- the organometallic salt of nitroprusside of formula I is coated in a biopolymer, preferably chosen from chitosan, an alginate of the metal M (Zn or Fe), pectin, agar-agar, carrageenan, a copolymer of lactic acid and glycolic acid (PLGA), a poly (L-lactide) polymer (PLLA), most preferably chitosan to form a film or spheres.
- a biopolymer preferably chosen from chitosan, an alginate of the metal M (Zn or Fe), pectin, agar-agar, carrageenan, a copolymer of lactic acid and glycolic acid (PLGA), a poly (L-lactide) polymer (PLLA), most preferably chitosan to form a film or spheres.
- the particle size of the organometallic salt of nitroprusside, the diameter of the spheres, the thickness of the film, the biopolymer / organometallic salt of nitroprusside mass ratio are identical to those described above.
- M II [Fe II (CN) 5 (NO)].
- the organometallic salt of nitroprusside of formula I is coated in a biopolymer such as chitosan, an alginate of the metal M (Zn or Fe), pectin, agar-agar, carrageenan, a copolymer lactic acid and glycolic acid (PLGA), a poly (L-lactide) polymer (PLLA), most preferably chitosan.
- a biopolymer such as chitosan, an alginate of the metal M (Zn or Fe), pectin, agar-agar, carrageenan, a copolymer lactic acid and glycolic acid (PLGA), a poly (L-lactide) polymer (PLLA), most preferably chitosan.
- the organometallic salt of nitroprusside of formula I is coated in the biopolymer to form a film or to form spheres.
- organometallic salt of nitroprusside of formula I When the organometallic salt of nitroprusside of formula I is coated in the biopolymer to form spheres, these spheres preferably have a diameter of between 1.5 mm and 4.5 mm. This diameter is measured using a graduated ruler and by SEM scanning electron microscopy. Still when the organometallic salt of nitroprusside of formula I is coated in the biopolymer to form spheres, the organometallic salt of formula I / biopolymer mass ratio is preferably between 2 and 60%.
- the organometallic nitroprusside salt of formula I when the organometallic nitroprusside salt of formula I is coated in the biopolymer to form a film, this film preferably has a thickness of between 30 ⁇ m and 1 mm. Still when the organometallic salt of nitroprusside of formula I is coated in the biopolymer to form a film, the organometallic salt of formula I / biopolymer mass ratio is preferably between 2 and 60%.
- organometallic nitroprusside salt of formula I When this ratio is greater than 10%, all the particles of organometallic nitroprusside salt of formula I are not completely coated in the biopolymer: some have a part on the surface, on the outside, of the film.
- the invention also proposes the use of the composite material according to the invention as an agent releasing nitrogen monoxide NO.
- Another subject of the invention is the composite material according to the invention for use as an antibacterial agent, or agent for promoting wound healing, or for the treatment of pulmonary hypertension.
- Yet another object of the invention is an implant comprising an organometallic salt of nitroprusside of the following formula I:
- the organometallic salt of nitroprusside of formula I is in the form of particles having a size (largest dimension) of between 50 nm to 6 ⁇ m.
- This implant can be made of a composite material according to the invention made to the desired size and shape.
- Still another object of the invention is a process for releasing gaseous nitrogen monoxide, characterized in that it comprises irradiation, with radiation emitting in the range of visible wavelengths (400 to 800 nm). , and / or the application of an aqueous suspension of at least one amino compound on particles of organometallic salt of nitroprusside of formula I of an organometallic salt of nitroprusside of following formula I:
- M II [Fe II (CN) 5 (NO)].
- the aqueous suspension of at least one amino compound is typically a biological fluid, or an aqueous suspension of lysine.
- the invention also proposes a method for decontaminating a substrate suspected of being contaminated by bacteria, characterized in that it comprises: a) the application, to the substrate, of particles of organometallic salt of nitroprusside of the following formula I:
- the morphological characteristics of the organometallic salt of nitroprusside of formula I and those of this salt when coated in the biopolymer are as defined above.
- nitroprusside salt by coprecipitation of sodium nitroprusside Na 2 [Fe (CN) 5 NO] .2H 2 O with a metal salt based on iron or zinc in water.
- Solutions of nitroprusside and of the metal salt are prepared in water at concentrations varying from 5.10 -3 M to 1.10 -1 M. These solutions are then added simultaneously at a rate varying from 2 mL / h to 0.8 mL / min in a volume of water varying from 10 to 100 mL.
- the nitroprusside solution can also be added dropwise to the solution of the metal salt.
- nitroprusside salt in polymer spheres by successive impregnations of the spheres in solutions of nitroprusside and of a metal salt based on Iron or Zinc in methanol.
- Solutions of nitroprusside and of the metal salt are prepared in methanol at concentrations varying from 1.10 -3 M to 1.10 -1 M.
- the polymer spheres (alcoogels prepared beforehand and suspended in methanol) are impregnated for 24 to 48 hours in a nitroprusside solution. After washing in methanol, these spheres are then impregnated in a solution of the metal salt for 24 to 48 hours. At this point, a cycle has been performed.
- the number of cycles can thus be increased by carrying out additional impregnations for 24 to 48 hours.
- - Synthesis of the nitroprusside salt in a polymer film by successive impregnations of the film in solutions of nitroprusside and of a metal salt based on Iron or Zinc in methanol. Solutions of nitroprusside and of the metal salt are prepared in methanol at concentrations varying from 1.10 -3 M to 1.10 -1 M.
- the polymer film (film prepared beforehand and suspended in methanol) is impregnated for 24 to 48 hours in a nitroprusside solution. After washing in methanol, the film is then impregnated in a solution of the metal salt for 24 to 48 hours. At this point, a cycle has been performed.
- the number of cycles can thus be increased by carrying out additional impregnations for 24 to 48 hours.
- FIG. 1 represents the curve of the release of NO from the organometallic salt of formula I obtained in Example 23, as a function of time, when exposed to light radiation emitting in the wavelength range of visible and suspended in water,
- Figure 2 shows the infrared spectra, before and after irradiation with light radiation emitting in the field of visible wavelengths, of the organometallic salt of formula I obtained in Example 23, in suspension in water,
- Figure 3 shows the NO release curve of the organometallic salt of formula I obtained in Example 3, as a function of time and in suspension in water, when exposed to light radiation emitting in the visible wavelength range,
- Figure 4 shows the infrared spectra, before and after irradiation with light radiation emitting in the field of visible wavelengths, of the organometallic salt of formula I obtained in Example 3,
- FIG. 5 represents the curve of the release of NO from the organometallic salt of formula I coated in chitosan spheres obtained in Example 17, as a function of time and in suspension in water, when exposed to light radiation emitting in the visible wavelength range,
- FIG.6 Figure 6 shows the infrared spectra, before and after irradiation with light radiation emitting in the field of visible wavelengths, of the organometallic salt of formula I obtained in Example 17,
- Figure 7 shows the NO release curve of the dihydrated sodium salt of nitroprusside of the prior art coated in a chitosan film obtained in Comparative Example 1, as a function of time and in suspension in the 'water, when exposed to irradiation (light radiation emitting in the visible wavelength range),
- FIG. 8 represents the curve of release of NO from the organometallic salt of formula I obtained in Example 23, as a function of time, when exposed to light radiation emitting in the visible wavelength domain. This curve is obtained with the film of Example 23 not placed in suspension in water, as is the case for FIG. 1, and
- FIG. 9 shows the infrared spectra, before and after irradiation with light radiation emitting in the field of visible wavelengths, of the organometallic salt of formula I obtained in Example 23. These spectra are obtained with the film of Example 23 not placed in suspension in water, as is the case for Figure 2.
- the invention is based on the discovery that organometallic salts of nitroprusside of the following formula I:
- Formula I in which M II represents Zn II or Fe II , and 2 ⁇ x ⁇ 18 could release, under various external stimuli, whether in solid phase or in suspension in water, nitrogen monoxide (NO), while releasing cyanide in an amount a thousand times less than that of the dihydrate sodium salt of nitroprusside widely used in the art today.
- NO nitrogen monoxide
- hydroxocobalamin can be used as a treatment against cyanide poisoning: Petrikovics et al. “Past, present and future of cyanide antagonism research: From the early remedies to the current therapies” World J. Methodol. 2015 June 26; 5 (2): 88-100.
- the inventors have also discovered that, surprisingly, when the organometallic salt of nitroprusside of formula I is irradiated at visible wavelengths, that is to say at wavelengths between 400 and 800 nm, NO is released, whether in solid form or in suspension.
- Irradiation by a table lamp can therefore be used.
- an aqueous solution of an amino compound such as a biological fluid or an aqueous solution of lysine can also be used to release organometallic salt of nitroprusside of formula I used in the invention.
- an application of both such irradiation and such an aqueous solution is generally used, in particular during the implementation of the method for decontaminating a substrate according to the invention.
- the invention provides the use of an organometallic salt of nitroprusside of formula I as an agent releasing NO.
- the invention also relates to the organometallic salt of nitroprusside of formula I for use as an antibacterial agent, or as a wound-healing agent, or as an agent for treating pulmonary hypertension.
- the organometallic salt of nitroprusside of formula I can also be used in a process for decontaminating a substrate suspected of being contaminated with bacteria, by application of the organometallic salt of nitroprusside of formula I and irradiation at the wavelengths indicated above and / or by applying an aqueous solution of an amino compound.
- the organometallic salt of nitroprusside of formula I can also be used in a method of therapeutic treatment for its antibacterial properties, promoting wound healing or pulmonary hypertension.
- the organometallic salt of nitroprusside of formula I is brought to the desired site and irradiated or covered with a solution of an amino compound, which in this case is preferably a biological fluid.
- the organometallic salt of nitroprusside of formula I is advantageously coated in a biopolymer, preferably chitosan, in order to be able to bring the particles of organometallic salt of nitroprusside of formula I to the particular site to be treated and to keep them in place.
- organometallic salt of nitroprusside of formula I can be coated with chitosan to form a film which will be deposited on the surface or on the site to be treated.
- organometallic salt of nitroprusside of formula I can also be coated in chitosan in the form of spheres.
- coated in a biopolymer is meant, in the invention, that the particles of the organometallic salt of formula I are either completely covered with the biopolymer, when the ratio by mass of organometallic salt of nitroprusside of formula I / biopolymer is between 2 and 60%, ie some particles are only partially covered with the biopolymer, when the organometallic salt of nitroprusside of formula I / biopolymer ratio by mass is greater than 10%.
- the organometallic salt of nitroprusside salt of formula I / biopolymer mass ratio is greater than 10%, the biopolymer is not in sufficient quantity to cover all the particles of the organometallic salt of formula I and those close to the surface, either spheres, or biopolymer film, are not completely covered.
- particles of the organometallic salt of nitroprusside of formula I having a size of between 50 nm and 6 ⁇ m coated in a biopolymer.
- another subject of the invention is a composite material comprising an organometallic salt of nitroprusside of formula I coated in a biopolymer, whether in the form of spheres or in the form of a film.
- the composite material according to the invention comprising an organometallic salt of nitroprusside of formula I coated in a biopolymer as an agent releasing NO is another subject of the invention.
- Yet another object of the invention is the composite material according to the invention comprising an organometallic salt of nitroprusside of formula I coated in a biopolymer for use as an antibacterial agent, or as an agent for promoting wound healing, or for use in the treatment of pulmonary hypertension.
- the particles of organometallic salt of nitroprusside of formula I, coated or not in a biopolymer can also be placed in or on an implant which will be placed at the desired site.
- the implant is a film formed from particles of organometallic nitroprusside salt of formula I coated in a biopolymer, shaped and sized.
- Such an implant can also be a hollow capsule made of a biopolymer in which particles of the organometallic salt of nitroprusside of formula I are placed.
- Such an implant comprising the organometallic salt of nitroprusside of formula I is also an object of the invention.
- the implant can also be a support made of a biocompatible material coated with the organometallic salt of nitroprusside of formula I or containing the organometallic salt of nitroprusside of formula I.
- Preferred biopolymers for use in coating the organometallic salt particles of nitroprusside of formula I are chitosan, an alginate of the metal M (Zn or Fe), pectin, agar-agar, carrageenan, a copolymer of lactic acid and gly colic acid (PLGA), a poly (L-lactide) polymer (PLLA), most preferably chitosan.
- the size of the particles of organometallic salt of nitroprusside of formula I can be controlled by the operating conditions of manufacture. This size varies according to the concentrations of the nitroprusside solutions and of the metal salt used, or according to the number of impregnation cycles carried out for the spheres and films.
- the colorless Zn (II) solution is added to the orange / red Na 2 [Fe (CN) 5 NO] solution which has been isolated from light.
- the mixture is centrifuged at 20,000 r ⁇ m for 10 minutes.
- the solution is removed and the resulting solid is washed with three times the volume of water. Another washing is carried out with ethanol in order to facilitate the drying process.
- the brown solid is dried under a vacuum of about 10 mbar.
- the particles obtained have a size (largest dimension) of between a few ⁇ m and a few tens of ⁇ m.
- Example 3 Synthesis of Fe [Fe (CN) 5 NO] .xH 2 O (2 ⁇ x ⁇ 18)
- ascorbic acid is added to prevent oxidation of iron.
- the mixture is then centrifuged at 20,000 rpm for 10 minutes.
- the supernatant is removed and the resulting solid is washed with 100 mL of distilled water and then centrifuged at 20,000 r ⁇ m for 10 minutes.
- a final wash is carried out under the same conditions and the brown solid is dried under vacuum.
- the particles obtained have sizes (largest dimension) of between 1, 2 and 5 mih.
- Example 4 Synthesis of precursor [PPh 4 ] 2 [Fe (CN) 5 NO] .xH 2 O (2 ⁇ x ⁇ 18) [PPh 4 ] 2 [Fe (CN) 5 NO] xH 2 O (2 ⁇ x ⁇ 18) is a starting compound used in the synthesis of organometallic salts of formula I.
- the Na 2 [Fe (CN) 5 NO] solution should be isolated from the light with aluminum foil in order to avoid the release of NO.
- the mixture is left under stirring and isolated from light for two hours.
- the mixture is centrifuged at 15,000 or 20,000 r ⁇ m for 10 minutes.
- Example 5 Synthesis of chitosan spheres lg of chitosan (“chitosan, low molecular weight,” Sigma Aldrich), are dissolved in 40 mL of a 1 vol.% Solution of acetic acid, with magnetic stirring overnight at ambient temperature. The aqueous chitosan solution is then added dropwise using a separating funnel fitted with a 0.8 mm diameter syringe tip, into a crystallizer containing 500 mL of aqueous NaOH solution (2M). with stirring (tip-solution distance of 10 cm). After the addition of 40 ml of chitosan solution, the beads contained in the sodium solution are left under stirring with stirring for 1 night.
- An exchange of solvents is then carried out in increasing solutions of ethanol or methanol so as not to deform the porous structure of the microspheres.
- the spheres are thus immersed for 15 minutes in Water-Ethanol or Water-Methanol baths of 200 mL of increasing alcohol concentration (10, 30, 50, 70, 90, 100% by volume) in order to exchange the water contained in the spheres by ethanol or methanol.
- the beads are kept in this alcoholic state or dried with supercritical CO 2 to replace ethanol with liquid CO 2.
- the CO 2 is then eliminated under supercritical conditions in an autoclave, above 31 C and 73 bar (typically 39 C and 85 bar), after a controlled expansion (at constant flow, less than 100 L / h) to atmospheric pressure.
- the spheres obtained have a size of between 2.6 and 4.7 mm for the alcoogels and between 1.5 and 3.2 mm for the aerogels.
- the mixture is stirred mechanically and isolated from the light (the Schlenk tube can be covered with aluminum foil for example) for 48 hours.
- the yellow / brown solution obtained was added to the Zn (NO 3 ) 2 -6H 2 O solution containing the previously prepared chitosan spheres.
- nitroprusside solutions are sensitive to light: they can start releasing NO just with daylight or a lamp.
- the solution is removed from the mixture and the chitosan spheres are washed three times with 20 ml of deoxygenated methanol for at least 15 min for each wash.
- the chitosan spheres obtained have a size varying from 1.75 to 2.75 mm.
- Example 7 Synthesis of Zn [Fe (CN) 5 NO] .xH 2 O (2 ⁇ x ⁇ 18) in chitosan spheres
- Example 4 was repeated but using a reaction time of 24 hours for the stirring of the mixture of Zn (NO 3 ) 2 -6H 2 O and chitosan spheres, and also a reaction time of 24 hours for the solution containing chitosan spheres, Zn (NO 3 ) 2 -6H 2 O and [ PPh 4 ] 2 [Fe (CN) 5 NO].
- the chitosan spheres obtained have a size varying from 1.75 to 2.75 mm.
- Example 8 Synthesis of Zn [Fe (CN) 5 NO] .xH 2 O (2 ⁇ x ⁇ 18) in chitosan spheres.
- acetonitrile is used as a solvent instead of methanol.
- 0.05 g (100 spheres) of chitosan spheres (alcoogels or aerogels) are added to the solution and an argon flow is increased from 2 to 10 minutes so as to maintain the solution under an inert atmosphere.
- the mixture is stirred mechanically and isolated from light (the Schlenk tube has been covered with aluminum foil) for 48 hours.
- the mixture is stirred mechanically and isolated from light for at least 15 minutes. After this time, the solvent is removed and 20 ml of deoxygenated acetonitrile are added again. This cycle is repeated three times.
- a solution of deoxygenated acetonitrile of [PPh 4 ] 2 [Fe (CN) 5 NO] is prepared by dissolving 0.286 g (0.32 mmol) of [PPh 4 ] 2 [Fe (CN) 5 NO] in 16 ml of deoxygenated acetonitrile.
- a flow of argon is passed for several seconds through the Schlenk tube containing the mixture so as to maintain it under inert conditions. It is important here to work with the minimum amount of light.
- the solution is removed from the mixture and the chitosan spheres are washed three times with deoxygenated acetonitrile for at least 15 min for each wash.
- the chitosan spheres obtained have a size varying from 1.75 to 2.75 mm.
- Example 9 Synthesis of Zn [Fe (CN) 5 NO] .xH 2 O (2 x 18) in chitosan spheres
- water is used as a solvent instead of methanol.
- 0.05 g (100 spheres) of chitosan (alcoogels or aerogels) are added to the solution and a flow of argon is passed through the Schlenk tube for 2 to 10 minutes so as to maintain the solution under an inert atmosphere.
- the mixture is allowed to stir mechanically and is isolated from light (the Schlenk tube has been covered with aluminum foil) for 48 hours.
- the solution is removed from the mixture and the chitosan spheres are washed three times with deoxygenated water for at least 15 min for each wash.
- the chitosan spheres obtained have a size varying from 1.75 to 2.75 mm.
- chitosan spheres (alcoogels or aerogels) are added to the solution and a flow of argon is passed through the Schlenk tube for several seconds so as to maintain the solution under an inert atmosphere.
- the mixture is left under mechanical stirring and isolated from light (the Schlenk tube has been covered with aluminum foil) for 48 hours.
- the spheres are then dried under vacuum or with supercritical CO 2.
- the chitosan spheres obtained have a size varying from 1.25 to 2.25 mm.
- Example 11 Synthesis of Fe [Fe (CN) 5 NO] xH 2 O (2 ⁇ x ⁇ 18) in chitosan spheres
- impregnation times of 24 hours are used compared to example 10 (48 hour impregnation time).
- chitosan spheres (alcoogels or aerogels) washed three times with methanol are added to the solution and a flow of argon is passed through the Schlenk tube for 2 to 10 minutes so as to maintain the solution under an inert atmosphere.
- the mixture is left under mechanical stirring and isolated from light (the Schlenk tube has been covered with aluminum foil) for 24 hours.
- Example 12 Synthesis of Fe [Fe (CN) 5 NO] .xH 2 O (2 ⁇ x ⁇ 18) in chitosan spheres
- ascorbic acid is used to prevent the oxidation of Fe 2+ .
- a flow of argon is passed for 2 to 10 minutes through the Schlenk tube so as to maintain the solution under an inert atmosphere.
- the mixture is allowed to stir mechanically and isolated from light (the Schlenk tube has been covered with aluminum foil) for 48 hours.
- the deoxygenated methanol solution is removed and a new deoxygenated methanol solution is added (25-30 ml). The mixture is left under mechanical stirring and isolated from light for at least 15 min.
- the methanolic solution of [PPh 4 ] 2 [Fe (CN) 5 NO] is prepared by dissolving 1.7 g of [PPh 4 ] 2 [Fe (CN) 5 NO] in 60 ml of deoxygenated methanol. The resulting yellow / brown solution was added to the solution containing the chitosan spheres prepared above.
- the solution is removed from the mixture and the chitosan spheres are washed three times with deoxygenated methanol for at least 15 min for each washing. During washing, mechanical agitation is used. The spheres are then dried under vacuum or with supercritical CO 2.
- the chitosan spheres obtained have a size varying from 1.25 to 2.25 mm.
- Example 12 the procedure was as in Example 12, that is to say by adding ascorbic acid but using a reaction time of only 24 hours.
- Example 15 Synthesis of Fe [Fe (CN) 5 NO] .xH 2 O (2 ⁇ x ⁇ 18) in chitosan spheres
- glucose is used instead of ascorbic acid to avoid oxidation of Fe 2+ .
- This synthesis takes place according to the following reaction scheme:
- the deoxygenated methanol solution is removed, and new deoxygenated methanol is added (25 to 30 ml). The mixture is left under mechanical stirring and isolated from light for at least 15 min.
- the mixture was mechanically stirred and isolated from light for another 48 hours. After these two days, the solution is removed from the mixture and the chitosan spheres are washed three times with deoxygenated methanol for at least 15 min for each washing. During washing, mechanical agitation is used. The spheres are then dried under vacuum or with supercritical CO 2. The chitosan spheres obtained have a size varying from 1.25 to 2.25 mm.
- Example 17 Synthesis of Fe [Fe (CN) 5 NO] .xH 2 O (2 ⁇ x ⁇ 18) in chitosan spheres
- the sodium nitroprusside precursor is used and impregnation times of 48 hours , then 24 hours are used.
- Example 15 The procedure was as in Example 15 but using a reaction time of only 24 hours. This example shows that the same compound is formed using a reaction time of 24 h instead of 48 h.
- a glass slide (76 x 26 mm) is introduced into the chitosan solution at the speed which has been chosen (between 2 and 5 mV)
- the slide is successively introduced into increasing solutions of ethanol (0, 20, 40, 60, 80, 100%).
- the film is then air dried.
- Example 20 Synthesis of chitosan films lg of chitosan (chitosan, low molecular weight, Sigma Aldrich), are dissolved in 40 mL of a solution of acetic acid at 1 vol.%, With magnetic stirring overnight at room temperature . A first sheet of filter paper is then impregnated in a 2 M NaOH solution prepared beforehand. The sheet is placed in a 60 mm diameter petri dish.
- chitosan chitosan, low molecular weight, Sigma Aldrich
- 6.5 mL of the chitosan solution are added to the sheet of filter paper in the petri dish.
- a second sheet of filter paper is also impregnated in 2M NaOH and placed on top of the chitosan solution in the filter paper. 3 mL of NaOH are also added on top. After 1 hour of gelation, the excess NaOH solution and the filter papers are removed. The chitosan film formed is rinsed in 3 mL of distilled water with orbital stirring for 15 minutes then the solvent removed. The operation is repeated until the washing water reaches a pH 6-7.
- the film is then immersed for 15 minutes in water-methanol baths of 3 ml of increasing concentration in methanol (10, 30, 50, 70, 90, 100% by volume) in order to exchange the water contained in the film by the methanol.
- the film is then stored in methanol.
- Example 21 Synthesis of Zn [Fe (CN) 5 NO] .xH 2 O (2 ⁇ x ⁇ 18) in chitosan films This synthesis takes place according to the following reaction scheme:
- a colorless solution is obtained and the chitosan film prepared on a glass slide in Example 20 is placed in the solution.
- the mixture is placed under mechanical stirring and isolated from light (the beaker has been covered with aluminum foil for 24 hours).
- the solution is removed from the mixture and the chitosan film is washed three times with deoxygenated methanol for 15 minutes for each wash. During washing, mechanical agitation is used.
- Particles of 1 to 6 mih are obtained on the surface of the chitosan film, the thickness of which is approximately 1 mm.
- the solution is removed and the chitosan film is washed three times with deoxygenated methanol for at least 15 min for each wash. During washing, mechanical agitation is used. The film is then dried in air. A film of about 1 mm thick of brown color is obtained.
- the particles of the organometallic salt of nitroprusside have a size of 1 to 6 mih at the surface of the film.
- the particles of the organometallic salt of nitroprusside have a size of 1 to 6 mih at the surface of the film. Comparative example 1
- the NO release measurement was performed according to either of the following two protocols.
- the measurement of the release of NO, known as liquid, from samples of organometallic salts of nitroprusside is the measurement of the release of NO from samples suspended in water and under irradiation by light radiation emitting in the wavelengths of the visible (compounds of Examples 3, 17, 23). It is carried out as follows.
- NO nitrites
- NO 2 - nitrites
- nitrites which constitute the products of oxidative degradation of NO. This is because NO reacts quickly with molecules such as oxygen or the superoxide anion to give nitrites.
- a spectrophotometric method using the Griess reaction it is a diazotization reaction where the nitrites form a diazonium salt with sulfanilamide which is then coupled with an amine (N-naphthylethylene diamine ) to give a dye absorbent at 540 nm.
- a calibration line is carried out in water using NaNO 2 between 0 and 50 ⁇ M.
- Figure 1 shows the release curve of NO from the organometallic salt of nitroprusside of formula I coated in a film of chitosan (compound of Example 23) suspended in water as a function of time and Figure 2 shows the infrared spectra before and after irradiation of this compound of Example 23 in suspension in water.
- the infrared spectrum obtained shows the appearance of the CN vibration band of Prussian blue.
- Figure 3 shows the release curve of NO from the organometallic salt of nitroprusside of formula I (compound of Example 3) and Figure 4 shows the infrared spectra before and after irradiation of this compound of Example 3.
- the infrared spectrum obtained shows the appearance of the CN vibration band of Prussian blue.
- Figure 5 shows the release curve of NO from the organometallic salt of nitroprusside of formula I (compound of Example 17) and Figure 6 shows the infrared spectra before and after irradiation of this compound of Example 17.
- the infrared spectrum obtained shows the appearance of the CN vibration band of Prussian blue.
- FIG. 7 shows the NO release curve of the sodium salt dihydrate of nitroprusside of the prior art coated in a chitosan film obtained in Comparative Example 1, as a function of time and in suspension in water, when exposed to irradiation.
- FIG. 8 shows the curve of the release of NO from the organometallic salt of formula I obtained in Example 23, as a function of time, when exposed to light radiation emitting in the range of visible wavelengths. This curve is obtained with the film of Example 23 not placed in suspension in water, as is the case for FIG. 1.
- FIG. 9 shows the infrared spectra, before and after irradiation with light radiation emitting in the field of visible wavelengths, of the organometallic salt of formula I obtained in Example 23. These spectra are obtained with the film of Example 23 not placed in suspension in water, as is the case for Figure 2.
- the quantities of NO released ( ⁇ mol / mg) under irradiation are greater in the case of organometallic salts alone or coated in the spheres or films of chitosan, compared to nitroprusside coated in chitosan.
- the quantification of CN- ions is carried out in solution in water by a photometric assay method: the free cyanides are decomposed at pH 3.8.
- the hydrogen cyanide present at pH 3.8 is separated by gas diffusion at a temperature between 30 ° C and 40 ° C through a hydrophobic membrane. Using the gas diffusion method, hydrogen cyanide is absorbed into sodium hydroxide solution.
- the film is then immersed for 15 minutes in Water-Methanol baths of 15 mL of increasing concentration of methanol (10, 30, 50, 70, 90, 100% by volume) in order to exchange the water contained in the film by methanol.
- the film is then stored in methanol.
- the film obtained is brought into contact in a solution of FeCl 2 .4H 2 O and ascorbic acid for 24 hours and then washed; it is then brought into contact in a solution of Na 2 [Fe (CN) 5 NO] .2H 2 O for 24 hours and then washed.
- the film is then dried in air. A film of about 1 mm thick of brown color is obtained.
- the particles of the organometallic salt of nitroprusside have a size of 1 to 6 mih at the surface of the film.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Plastic & Reconstructive Surgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1912761A FR3103104B1 (fr) | 2019-11-15 | 2019-11-15 | Sel organometallique de nitroprusside en tant qu’agent liberant du no |
| PCT/EP2020/082060 WO2021094535A1 (fr) | 2019-11-15 | 2020-11-13 | Sel organometallique de nitroprusside en tant qu'agent liberant du no |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4058463A1 true EP4058463A1 (fr) | 2022-09-21 |
Family
ID=71894854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP20803605.3A Pending EP4058463A1 (fr) | 2019-11-15 | 2020-11-13 | Sel organometallique de nitroprusside en tant qu'agent liberant du no |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP4058463A1 (fr) |
| FR (1) | FR3103104B1 (fr) |
| WO (1) | WO2021094535A1 (fr) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011130605A2 (fr) * | 2010-04-16 | 2011-10-20 | Georgetown University | Compositions et procédés pour traiter l'hypertension pulmonaire |
| US10344002B2 (en) * | 2016-09-26 | 2019-07-09 | Nusirt Sciences, Inc. | Compositions and methods for treating metabolic disorders |
| WO2019211632A1 (fr) * | 2018-05-04 | 2019-11-07 | Oxford University Innovation Ltd | Traitement de l'hypertension nocturne |
-
2019
- 2019-11-15 FR FR1912761A patent/FR3103104B1/fr active Active
-
2020
- 2020-11-13 EP EP20803605.3A patent/EP4058463A1/fr active Pending
- 2020-11-13 WO PCT/EP2020/082060 patent/WO2021094535A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| FR3103104A1 (fr) | 2021-05-21 |
| WO2021094535A1 (fr) | 2021-05-20 |
| FR3103104B1 (fr) | 2022-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dördelmann et al. | CuAAC click functionalization of azide-modified nanodiamond with a photoactivatable CO-releasing molecule (PhotoCORM) based on [Mn (CO) 3 (tpm)]+ | |
| Gole et al. | Microtubular self‐assembly of covalent organic frameworks | |
| Lv et al. | Improvement in Thermal Stability of Sucralose by γ-Cyclodextrin Metal-Organic Frameworks: Lv et al. | |
| Wang et al. | Chemiluminescent two-dimensional metal–organic framework with multiple metal catalytic centers and its peroxidase-like activity for sensing of small molecules | |
| So et al. | De novo synthesis and particle size control of iron metal organic framework for diclofenac drug delivery | |
| CN105969331B (zh) | 一种适用于靶向药物载体的纳米材料的制备方法 | |
| Vishnevetskii et al. | l-Cysteine/AgNO 2 low molecular weight gelators: self-assembly and suppression of MCF-7 breast cancer cells | |
| WO2016158806A1 (fr) | Nouveau composite de composé de fer et d'oxyde de graphène | |
| Kusrini et al. | Modification of chitosan by using samarium for potential use in drug delivery system | |
| Zhou et al. | Sulfur/nitrogen co-doped carbon-based copper nanozyme with high peroxidase-like activity for dual-channel paper-based detection of melatonin | |
| Vodyashkin et al. | Synthesis and activation of pH-sensitive metal–organic framework Sr (BDC)∞ for oral drug delivery | |
| CN116211839A (zh) | 一种姜黄素载药系统及其制备方法 | |
| WO2016151245A1 (fr) | Méthode de détection in vitro de h2s à partir de mof luminescent | |
| JP4702754B2 (ja) | 物質内包カーボンナノホーン複合体及びその製造方法 | |
| CN108587613A (zh) | 一种丁基氨基硫脲修饰碳量子点荧光探针的制备方法及其在选择性识别铜离子中的应用 | |
| CN104548127B (zh) | 碳酸钙‑阿霉素‑二氧化硅纳米颗粒及其制备方法 | |
| EP4058463A1 (fr) | Sel organometallique de nitroprusside en tant qu'agent liberant du no | |
| He et al. | Sensitive chemiluminescence detection platform for H2O2 and glucose through facile inorganic salt etching of cobalt Prussian blue analogues | |
| CN110327982B (zh) | 一种以pei-环丙沙星胶束为模板的钯纳米粒子及其制备方法 | |
| FR2964665A1 (fr) | Nanoparticules luminescentes utilisables en tant que marqueurs et procede pour leur preparation | |
| Wu et al. | Mussel Inspired In Situ Preparation of Antibacterial Silver Nanoparticles by DOPA‐Containing Silk Fibroin | |
| Varaprasad et al. | Development, Characterization, and Biomedical Applications of PVP–AgCl Nanomaterials: Antibacterial and Anticancer Properties | |
| CN109966267A (zh) | 纳米声敏剂在制备基于光声引导的声动力学治疗肿瘤药物中的用途 | |
| CN117180226A (zh) | 银纳米粒子负载甘露糖偶联pda-epl修饰介孔氧化硅复合材料及其制备方法和应用 | |
| Ghorbani et al. | Nanostructures Originated from Grafting Amino Group Containing Biomolecules on Graphene Oxide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20220601 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20251209 |